2021
On January 4, 2021, Endo launches authorized generic version of Amitiza® (lubiprostone) capsules in the U.S.
On January 5, 2021, Endo announces licensing agreement for Paladin Labs to commercialize Abaloparatide in Canada.
On January 5, 2021, Endo launches "Really Cellulite" campaign.
On March 5, 2021, Endo launches QWO®, the first and only FDA-approved injectable for the treatment of moderate to severe cellulite in the buttocks of adult women.
On April 12, 2021, Endo and ADVANZ PHARMA announce partnership for Paladin Labs to commercialize Xydalba® (dalbavancin hydrochloride) in Canada.
On April 13, 2021, Endo announces publication of Phase 3 Qwo® (collagenase clostridium histolyticum-aaes) data in peer-reviewed Dermatologic Surgery.
On June 9, 2021, Paladin Labs announces approval of Wakix® (pitolisant) in Canada.
On September 22, 2021, Endo launches first and only generic version of Chantix® (varenicline) tablets in the U.S.
On October 25, 2021, Endo announces first-ever XIAFLEX® (collagenase clostridium histolyticum) television commercial, Bent Carrot, and branded campaign to raise awareness of Peyronie's Disease.
On November 8, 2021, Endo announces agreement with Premier to supply VASOSTRICT® (vasopressin injection, USP) vials, essential for COVID-19 care.
On November 17, 2021, Endo announces fill-finish manufacturing agreement with U.S. government to support production of critical medicines.
On November 18, 2021, Endo begins shipment of generic MIACALCIN® (calcitonin salmon) injection.
On December 23, 2021, Endo announces agreement for Paladin Labs to commercialize SK Biopharmaceuticals' XCOPRI® (Cenobamate) in Canada.